Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDAP 
EDAP TMS SA (EDAP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: EDAP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.75
1 Year Target Price $5.75
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.62% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.02M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 3 | Beta 0.02 | 52 Weeks Range 1.26 - 5.27 | Updated Date 07/14/2025 |
52 Weeks Range 1.26 - 5.27 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.33% | Operating Margin (TTM) -44.22% |
Management Effectiveness
Return on Assets (TTM) -16.54% | Return on Equity (TTM) -49.28% |
Valuation
Trailing PE - | Forward PE 38.02 | Enterprise Value 40938248 | Price to Sales(TTM) 0.91 |
Enterprise Value 40938248 | Price to Sales(TTM) 0.91 | ||
Enterprise Value to Revenue 0.56 | Enterprise Value to EBITDA 1165.78 | Shares Outstanding 37392100 | Shares Floating 29010276 |
Shares Outstanding 37392100 | Shares Floating 29010276 | ||
Percent Insiders - | Percent Institutions 41.38 |
Upturn AI SWOT
EDAP TMS SA
Company Overview
History and Background
EDAP TMS SA was founded in 1979 and is headquartered in Vaulx-en-Velin, France. It develops, manufactures, and markets minimally invasive medical devices for urology using focused ultrasound and laser technologies. The company has evolved from pioneering extracorporeal shockwave lithotripsy to high-intensity focused ultrasound (HIFU) for prostate cancer treatment.
Core Business Areas
- HIFU: Develops and markets High-Intensity Focused Ultrasound (HIFU) devices, primarily the Ablatherm and Focal One systems, for the treatment of localized prostate cancer and other urological conditions.
- Urology Devices: Develops and markets devices for urological indications using laser technologies. Products include laser fibers and accessories.
- Distribution of Consumables: Distribution of consumables that are used in conjunction with EDAP systems.
Leadership and Structure
Marc Oczachowski serves as the Chief Executive Officer. The company has a board of directors with expertise in medical technology and finance.
Top Products and Market Share
Key Offerings
- Focal One: Focal One is a HIFU system for focal therapy of prostate cancer. It allows precise ablation of targeted areas within the prostate. Market share is estimated at around 25% in the HIFU market for prostate cancer treatment. Competitors include Profound Medical (PROF) and Sonacare Medical.
- Ablatherm: Ablatherm Integrated Imaging is a HIFU system used for whole gland ablation of the prostate. Market share is significant but decreasing as focal therapy gains traction. Competitors include Profound Medical (PROF) and Sonacare Medical.
- Laser Fibers: EDAP also supplies laser fibers for the treatment of urinary conditions such as Benign Prostatic Hyperplasia (BPH). Competitors include Boston Scientific (BSX), Lumenis, and Olympus
Market Dynamics
Industry Overview
The market for minimally invasive urological treatments is growing, driven by an aging population, increasing incidence of prostate cancer, and patient preference for less invasive procedures. Technologies like HIFU and laser ablation are gaining acceptance.
Positioning
EDAP TMS SA is a leader in HIFU technology for prostate cancer treatment, with a strong reputation for innovation and clinical expertise. They face competition from other HIFU and alternative treatment providers.
Total Addressable Market (TAM)
The total addressable market for prostate cancer treatment is estimated to be in the billions of dollars annually. EDAP is positioning itself to capture a significant portion of this market through its HIFU technology, particularly with the rise of focal therapy. EDAP has a revenue less than $100M USD and based on competitors, they may be able to growth several-fold into this TAM.
Upturn SWOT Analysis
Strengths
- Pioneering HIFU technology
- Established brand recognition
- Extensive clinical data supporting HIFU efficacy
- Experienced leadership team
Weaknesses
- Limited market penetration compared to established surgical options
- Reliance on specific urological procedures
- Relatively small size compared to major medical device companies
- Geographic concentration of revenue
Opportunities
- Expanding applications of HIFU technology
- Increasing adoption of focal therapy for prostate cancer
- Geographic expansion into new markets
- Strategic partnerships with hospitals and urology practices
Threats
- Competition from established surgical techniques
- Emergence of new minimally invasive technologies
- Reimbursement challenges for HIFU procedures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- PROF
- BSX
- LMNR
Competitive Landscape
EDAP TMS SA possesses a strong hold within the HIFU space but faces competition from larger medical device companies with broader portfolios. EDAP needs to maintain its technological advantage and marketing efforts to remain competitive.
Growth Trajectory and Initiatives
Historical Growth: EDAP TMS SA's growth has been driven by the adoption of HIFU technology for prostate cancer treatment. Growth is dependent on acceptance in the medical community.
Future Projections: Analysts project continued growth for EDAP TMS SA, driven by increased adoption of HIFU and expansion into new markets. Actual future growth can vary.
Recent Initiatives: Focus on expanding focal therapy capabilities with Focal One, entering new geographic markets, and increasing sales and marketing efforts.
Summary
EDAP TMS SA is a specialized company in the minimally invasive medical device space, specifically focused on HIFU technology for urology. Its Focal One system is gaining traction, indicating growth potential. The company faces competition from larger, more established players and relies heavily on the urology market for revenue. Reimbursement rates, and expanding into new markets will be key to sustainable success. Continued technological advancement in the HIFU space is critical to keep its first mover advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are based on available data and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EDAP TMS SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1997-07-31 | CEO & Director Mr. Ryan Rhodes | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 310 | Website https://focalone.com |
Full time employees 310 | Website https://focalone.com | ||
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The DIST segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.